GenFleet Therapeutics (Shanghai) (HAM:Y3L) Short-Term Debt: €10.17 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Y3L GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
19 GF Score
Price €2.92
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) Short-Term Debt?

GenFleet Therapeutics (Shanghai) HAM:Y3L -2.80% 19 Short-Term Debt is €10.17 Mil as of Dec. 2025. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

GenFleet Therapeutics (Shanghai)'s Short-Term Debt for the quarter that ended in Dec. 2025 was €10.17 Mil.

GenFleet Therapeutics (Shanghai)'s quarterly Short-Term Debt increased from Dec. 2024 (€6.71 Mil) to Jun. 2025 (€9.54 Mil) and increased from Jun. 2025 (€9.54 Mil) to Dec. 2025 (€10.17 Mil).

GenFleet Therapeutics (Shanghai)'s annual Short-Term Debt increased from Dec. 2023 (€0.68 Mil) to Dec. 2024 (€6.71 Mil) and increased from Dec. 2024 (€6.71 Mil) to Dec. 2025 (€10.17 Mil).

GenFleet Therapeutics (Shanghai) Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

GenFleet Therapeutics (Shanghai) Short-Term Debt Related Terms

GenFleet Therapeutics (Shanghai) Short-Term Debt Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) Short-Term Debt Chart

GenFleet Therapeutics (Shanghai) Annual Data
Trend Dec23 Dec24 Dec25
Short-Term Debt
0.68 6.71 10.17

GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt 0.68 0.00 6.71 9.54 10.17
HAM:Y3L
19GF Score
GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €10.17 Mil mean?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Short-Term Debt of €10.17 Mil as of Dec. 2025.
Is GenFleet Therapeutics (Shanghai)'s Short-Term Debt too high?
GenFleet Therapeutics (Shanghai)'s current Short-Term Debt is €10.17 Mil. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Short-Term Debt compare to VRTX and REGN?
GenFleet Therapeutics (Shanghai)'s Short-Term Debt of €10.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. GenFleet Therapeutics (Shanghai)'s current Short-Term Debt is €10.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Short-Term Debt of €10.17 Mil. The current Short-Term Debt is €10.17 Mil. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Short-Term Debt is €10.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges 02595:Hong Kong
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score

Get the complete analysis for HAM:Y3L

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price